Genetic determination of the hypothalamic-pituitary-thyroid axis: Where do we stand?

Endocrine Reviews

Volumn 36, Issue 2, 2015, Pages 214-244

  Medici, Marco ^a   Edward Visser, W ^a   Visser, Theo J ^a   Peeters, Robin P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CARRIER PROTEIN; CD150 ANTIGEN; CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CCR6; CYCLIC AMP; CYCLIC GMP; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCARBOXYLATE TRANSPORTER 10; MONOCARBOXYLATE TRANSPORTER 8; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PHOSPHODIESTERASE; PROLACTIN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SODIUM BILE ACID COTRANSPORTER; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROID TRANSCRIPTION FACTOR 2; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXE1; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; VASCULOTROPIN A;

3' UNTRANSLATED REGION; ALLELIC IMBALANCE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BODY COMPOSITION; BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; CARDIOVASCULAR MORTALITY; CHOLESTEROL METABOLISM; CLINICAL FEATURE; COGNITION; CONGENITAL HYPOTHYROIDISM; DEPRESSION; DIABETES MELLITUS; DNA FLANKING REGION; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; EXOME; EXON; FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GOITER; HASHIMOTO DISEASE; HETEROZYGOTE; HIP OSTEOARTHRITIS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HORMONE TRANSPORT; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; INFECTION SENSITIVITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LINKAGE ANALYSIS; LIOTHYRONINE BLOOD LEVEL; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN READING FRAME; OSTEOARTHRITIS; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUBCLINICAL HYPOTHYROIDISM; SYSTEMATIC REVIEW; THYROID CANCER; THYROID DISEASE; THYROID DYSGENESIS; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; THYROXINE BLOOD LEVEL; X CHROMOSOME; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; THYROID GLAND;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTHYROIDISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHYROIDISM; POLYMORPHISM, GENETIC; THYROID GLAND; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE; THYROTROPIN;

EID: 85001759320     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2014-1081     Document Type: Review

References (287)

1. Murphy E, Glüer CC, Reid DM, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010;95:3173-3181.
2. Medici M, Direk N, Visser WE, et al. Thyroid function within the normal range and the risk of depression: a population-based cohort study. J Clin Endocrinol Metab. 2014;99(4):1213-1219.
3. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2015;100(3):1088-1096.
4. Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med. 2008;168:2219-2224.
5. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf). 2010;72:696-701.
6. Asvold BO, Bjøro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med. 2008;168:855-860.
7. Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab. 2013;98:3562-3571.
8. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068-1072.
9. Andersen SL, Olsen J, Wu CS, Laurberg P. Smoking reduces the risk of hypothyroidism and increases the risk of hyperthyroidism: evidence from 450,842 mothers giving birth in Denmark. Clin Endocrinol (Oxf). 2014;80:307-314.
10. Bülow Pedersen I, Knudsen N, et al. Large differences in incidences of overt hyper-and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab. 2002;87:4462-4469.
11. Hansen PS, Brix TH, Sørensen TI, Kyvik KO, Hegedüs L. Major genetic influence on the regulation of the pituitarythyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab. 2004;89:1181-1187.
12. Panicker V, Wilson SG, Spector TD, et al. Heritability of serum TSH, free T4 and free T3 concentrations: a study of a large UK twin cohort. Clin Endocrinol (Oxf). 2008;68: 652-659.
13. Samollow PB, Perez G, Kammerer CM, et al. Genetic and environmental influences on thyroid hormone variation in Mexican Americans. J Clin Endocrinol Metab. 2004;89: 3276-3284.
14. Engum A, Bjøro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function-a clinical fact or an artefact? Acta Psychiatr Scand. 2002;106: 27-34.
15. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-585.
16. Grasberger H, Refetoff S. Genetic causes of congenital hypothyroidism due to dyshormonogenesis. Curr Opin Pediatr. 2011;23:421-428.
17. Grüters A, Krude H, Biebermann H. Molecular genetic defects in congenital hypothyroidism. Eur J Endocrinol. 2004;151(suppl 3):U39-U44.
18. Moreno JC, Visser TJ. Genetics and phenomics of hypothyroidism and goiter due to iodotyrosine deiodinase (DEHAL1) gene mutations. Mol Cell Endocrinol. 2010; 322:91-98.
19. Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I-symporter (NIS): mechanism and medical impact. Endocr Rev. 2014;35:106-149.
20. Visser WE, van Mullem AA, Visser TJ, Peeters RP. Different causes of reduced sensitivity to thyroid hormone: diagnosis and clinical management. Clin Endocrinol (Oxf). 2013;79:595-605.
21. Arturi F, Scarpelli D, Coco A, et al. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid. 2003;13:341-343.
22. Beck-Peccoz P, Persani L, Calebiro D, Bonomi M, Mannavola D, Campi I. Syndromes of hormone resistance in the hypothalamic-pituitary-thyroid axis. Best Pract Res Clin Endocrinol Metab. 2006;20:529-546.
23. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010;322:125-134.
24. Kratzsch J, Pulzer F. Thyroid gland development and defects. Best Pract Res Clin Endocrinol Metab. 2008; 22:57-75.
25. Persani L, Calebiro D, Cordella D, et al. Genetics and phenomics of hypothyroidism due to TSH resistance. Mol Cell Endocrinol. 2010;322:72-82.
26. Ris-Stalpers C, Bikker H. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. Mol Cell Endocrinol. 2010;322:38-43.
27. Targovnik HM, Esperante SA, Rivolta CM. Genetics and phenomics of hypothyroidism and goiter due to thyroglobulin mutations. Mol Cell Endocrinol. 2010;322:44-55.
28. Hébrant A, van Staveren WC, Maenhaut C, Dumont JE, Leclère J. Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur J Endocrinol. 2011; 164:1-9.
29. van der Deure WM, Peeters RP, Visser TJ. Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. J Mol Endocrinol. 2010;44:1-11.
30. Dumitrescu AM, Refetoff S. The syndromes of reduced sensitivity to thyroid hormone. Biochim Biophys Acta. 2013;1830:3987-4003.
31. Park SM, Chatterjee VK. Genetics of congenital hypothyroidism. J Med Genet. 2005;42:379-389.
32. Schoenmakers N, Moran C, Peeters RP, Visser T, Gurnell M, Chatterjee K. Resistance to thyroid hormone mediated by defective thyroid hormone receptorα. Biochim Biophys Acta. 2013;1830:4004-4008.
33. Visser TJ. Thyroid hormone transporters and resistance. Endocr Dev. 2013;24:1-10.
34. Mannavola D, Vannucchi G, Fugazzola L, et al. TBG deficiency: description of two novel mutations associated with complete TBG deficiency and review of the literature. J Mol Med (Berl). 2006;84:864-871.
35. Heufelder AE, Klee GG, Wynne AG, Gharib H. Familial dysalbuminemic hyperthyroxinemia: cumulative experience in 29 consecutive patients. Endocr Pract. 1995;1:4-8.
36. Ercan-Fang S, Schwartz HL, Mariash CN, Oppenheimer JH. Quantitative assessment of pituitary resistance to thyroid hormone from plots of the logarithm of thyrotropin versus serum free thyroxine index. J Clin Endocrinol Metab. 2000;85:2299-2303.
37. Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res. 2012;54:204-213.
38. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res. 2012; 54:191-203.
39. Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol. 2013;9:277-287.
40. Simmonds MJ, Gough SC. The search for the genetic contribution to autoimmune thyroid disease: the never ending story? Brief Funct Genomics. 2011;10:77-90.
41. Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid. 2010;20:715-725.
42. Kleinau G, Neumann S, Grüters A, Krude H, Biebermann H. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev. 2013;34:691-724.
43. Iosco C, Cosentino C, Sirna L, et al. Anoctamin 1 is apically expressed on thyroid follicular cells and contributes to ATP-and calcium-activated iodide efflux. Cell Physiol Biochem. 2014;34:966-980.
44. Twyffels L, Strickaert A, Virreira M, et al. Anoctamin-1/TMEM16A is the major apical iodide channel of the thyrocyte. Am J Physiol Cell Physiol. 2014;307:C1102-C1112.
45. Fugazzola L, Muzza M, Weber G, Beck-Peccoz P, Persani L. DUOXS defects: genotype-phenotype correlations. Ann Endocrinol (Paris). 2011;72:82-86.
46. Martinez ME, Charalambous M, Saferali A, et al. Genomic imprinting variations in the mouse type 3 deiodinase gene between tissues and brain regions. Mol Endocrinol. 2014; 28:1875-1886.
47. Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol. 2011;25:1-14.
48. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38-89.
49. Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29:898-938.
50. Kuiper GG, Kester MH, Peeters RP, Visser TJ. Biochemical mechanisms of thyroid hormone deiodination. Thyroid. 2005;15:787-798.
51. Ma SF, Xie L, Pino-Yanes M, et al. Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol. 2011;45:1203-1211.
52. Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab. 2001;86:5572-5576.
53. Furumoto H, Ying H, Chandramouli GV, et al. An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol. 2005; 25:124-135.
54. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis. 2002;23:25-33.
55. Rosen MD, Chan IH, Privalsky ML. Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Mol Endocrinol. 2011;25:1311-1325.
56. Howard D, La Rosa FG, Huang S, et al. Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult. J Clin Endocrinol Metab. 2011;96:1966-1970.
57. Huang SA, Fish SA, Dorfman DM, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab. 2002;87:4457-4461.
58. Maynard MA, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014; 371:86-87.
59. Chan IH, Privalsky ML. Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene. 2009;28: 4162-4174.
60. Luongo C, Trivisano L, Alfano F, Salvatore D. Type 3 deiodinase and consumptive hypothyroidism: a common mechanism for a rare disease. Front Endocrinol (Lausanne). 2013;4:115.
61. Panicker V, Wilson SG, Spector TD, et al. Genetic loci linked to pituitary-thyroid axis set points: a genome-wide scan of a large twin cohort. J Clin Endocrinol Metab. 2008; 93:3519-3523.
62. Liu Z, Sun Y, Dong Q, He M, Cheng CH, Fan F. A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism. J Hum Genet. 2008;53:475-478.
63. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31:629-662.
64. Hoggart CJ, Parra EJ, Shriver MD, et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet. 2003;72:1492-1504.
65. Peeters RP, van Toor H, Klootwijk W, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003;88:2880-2888.
66. Appelhof BC, Peeters RP, Wiersinga WM, et al. Polymorphisms in type 2 deiodinase are not associated with wellbeing, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. J Clin Endocrinol Metab. 2005;90:6296-6299.
67. Butler PW, Smith SM, Linderman JD, et al. The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. Thyroid. 2010;20:1407-1412.
68. de Jong FJ, Peeters RP, den Heijer T, et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2007;92: 636-640.
69. Feng J, Yan J, Michaud S, et al. Scanning of estrogen receptor α (ERα) and thyroid hormone receptor α (TRα) genes in patients with psychiatric diseases: four missense mutations identified in ERα gene. Am J Med Genet. 2001; 105:369-374.
70. Guerra A, Sapio MR, Carrano M, et al. Prevalence of Dio2(T92A) polymorphism and its association with thyroid autoimmunity. J Endocrinol Invest. 2013;36:303-306.
71. Gumieniak O, Perlstein TS, Williams JS, et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension. 2007;49:461-466.
72. Hansen PS, van der Deure WM, Peeters RP, et al. The impact of a TSH receptor gene polymorphism on thyroidrelated phenotypes in a healthy Danish twin population. Clin Endocrinol (Oxf). 2007;66:827-832.
73. Heemstra KA, Hoftijzer HC, van der Deure WM, et al. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf). 2009; 71:279-283.
74. Hoftijzer HC, Heemstra KA, Visser TJ, et al. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2011;96:E1527-E1533.
75. Lago-Lestón R, Iglesias MJ, San-José E, et al. Prevalence and functional analysis of the S107P polymorphism (rs6647476) of the monocarboxylate transporter 8 (SLC16A2) gene in the male population of north-west Spain (Galicia). Clin Endocrinol (Oxf). 2009;70:636-643.
76. Medici M, van der Deure WM, Verbiest M, et al. A largescale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol. 2011;164:781-788.
77. Mentuccia D, Thomas MJ, Coppotelli G, et al. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid. 2005;15:1223-1227.
78. Panicker V, Cluett C, Shields B, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab. 2008;93:3075-3081.
79. Peeters RP, van den Beld AW, Attalki H, et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab. 2005;289:E75-E81.
80. Peeters RP, van den Beld AW, van Toor H, et al. A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans. J Clin Endocrinol Metab. 2005;90:256-263.
81. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol. 2006;155:655-662.
82. Peltsverger MY, Butler PW, Alberobello AT, et al. The-258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRHinduced acute rise in TSH. Eur J Endocrinol. 2012;166: 839-845.
83. Philibert RA, Beach SR, Gunter TD, et al. The relationship of deiodinase 1 genotype and thyroid function to lifetime history of major depression in three independent populations. Am J Med Genet B Neuropsychiatr Genet. 2011; 156B:593-599.
84. Procopciuc LM, Hazi GM, Caracostea G, et al. Correlation between the TSHRc-Asp727Glu polymorphism and plasma thyroid stimulating hormone levels in Romanian preeclamptic women. Gynecol Endocrinol. 2011;27:225-231.
85. Procopciuc LM, Hazi GM, Caracostea G, et al. The effect of the D1-C785T polymorphism in the type 1 iodothyronine deiodinase gene on the circulating thyroid hormone levels in Romanian women with preeclampsia. Association with the degree of severity and pregnancy outcome of preeclampsia. Gynecol Endocrinol. 2012;28:386-390.
86. Roef G, Taes Y, Toye K, et al. Heredity and lifestyle in the determination of between-subject variation in thyroid hormone levels in euthyroid men. Eur J Endocrinol. 2013; 169:835-844.
87. Roef GL, Rietzschel ER, De Meyer T, et al. Associations between single nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and OATP1C1) and circulating thyroid hormones. Clin Chim Acta. 2013; 425:227-232.
88. Sørensen HG, van der Deure WM, Hansen PS, et al. Identification and consequences of polymorphisms in the thyroid hormone receptor α and β genes. Thyroid. 2008;18: 1087-1094.
89. Torlontano M, Durante C, Torrente I, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts Lthyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab. 2008; 93:910-913.
90. van der Deure WM, Friesema EC, de Jong FJ, et al. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology. 2008;149:4695-4701.
91. van der Deure WM, Hansen PS, Peeters RP, et al. Thyroid hormone transport and metabolism by organic anion transporter 1C1 and consequences of genetic variation. Endocrinology. 2008;149:5307-5314.
92. van der Deure WM, Hansen PS, Peeters RP, et al. The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins. Clin Endocrinol (Oxf). 2009;70:954-960.
93. van der Deure WM, Peeters RP, Visser TJ. Genetic variation in thyroid hormone transporters. Best Pract Res Clin Endocrinol Metab. 2007;21:339-350.
94. van der Deure WM, Uitterlinden AG, Hofman A, et al. Effects of serum TSH and FT4 levels and the TSHRAsp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf). 2008;68:175-181.
95. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972-1983.
96. Gabriel EM, Bergert ER, Grant CS, van Heerden JA, Thompson GB, Morris JC. Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. J Clin Endocrinol Metab. 1999;84:3328-3335.
97. Nogueira CR, Kopp P, Arseven OK, Santos CL, Jameson JL, Medeiros-Neto G. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil. Thyroid. 1999;9:1063-1068.
98. Sykiotis GP, Neumann S, Georgopoulos NA, et al. Functional significance of the thyrotropin receptor germline polymorphism D727E. Biochem Biophys Res Commun. 2003;301:1051-1056.
99. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Discovery ofcommonvariants associated with low TSH levels and thyroid cancer risk. Nat Genet. 2012;44:319-322.
100. Porcu E, Medici M, Pistis G, et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet. 2013;9:e1003266.
101. Arnaud-Lopez L, Usala G, Ceresini G, et al. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet. 2008;82: 1270-1280.
102. Panicker V, Wilson SG, Walsh JP, et al. A locus on chromosome 1p36 is associated with thyrotropin and thyroid function as identified by genome-wide association study. Am J Hum Genet. 2010;87:430-435.
103. Abe T, Kakyo M, Sakagami H, et al. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem. 1998;273:22395-22401.
104. Friesema EC, Docter R, Moerings EP, et al. Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999;254:497-501.
105. Visser WE, Wong WS, van Mullem AA, et al. Study of the transport of thyroid hormone by transporters of the SLC10 family. Mol Cell Endocrinol. 2010;315:138-145.
106. Jansen J, Friesema EC, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid. 2005; 15:757-768.
107. Hagenbuch B. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab. 2007;21:209-221.
108. Heuer H, Visser TJ. The pathophysiological consequences of thyroid hormone transporter deficiencies: insights from mouse models. Biochim Biophys Acta. 2013;1830:3974-3978.
109. Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport by monocarboxylate transporters. Best Pract Res Clin Endocrinol Metab. 2007;21:223-236.
110. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003; 1609:1-18.
111. Hsiang B, Zhu Y, Wang Z, et al. Anovelhumanhepatic organic anion transporting polypeptide(OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of ratandhumanhydroxymethylglutaryl-CoAreductase inhibitor transporters. J Biol Chem. 1999;274:37161-37168.
112. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.Am J Physiol Gastrointest Liver Physiol. 2000;278:G156-G164.
113. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002;16:2283-2296.
114. Fujiwara K, Adachi H, Nishio T, et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001;142:2005-2012.
115. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999;274:17159-17163.
116. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120:525-533.
117. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol. 2005; 1:429-445.
118. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77:468-478.
119. Cooper-Kazaz R, van der Deure WM, Medici M, et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord. 2009;116:113-116.
120. Dentice M, Bandyopadhyay A, Gereben B, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol. 2005;7:698-705.
121. Canani LH, Capp C, Dora JM, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005;90:3472-3478.
122. Gereben B, Kollár A, Harney JW, Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol. 2002;16: 1667-1679.
123. Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5' UTR of the gene. Thyroid. 2006;16:625-632.
124. Charalambous M, Hernandez A. Genomic imprinting of the type 3 thyroid hormone deiodinase gene: regulation and developmental implications. Biochim Biophys Acta. 2013;1830:3946-3955.
125. Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab. 2007;21:277-305.
126. Dayan CM, Panicker V. Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol. 2009;5:211-218.
127. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76-131.
128. He B, Li J, Wang G, et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:986-990.
129. Brouwer JP, Appelhof BC, Peeters RP, et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur J Endocrinol. 2006;154:819-825.
130. Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med. 1998;158:1413-1418.
131. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf). 2000;53:733-737.
132. de Jong FJ, den Heijer T, Visser TJ, et al. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2006;91:2569-2573.
133. Medici M, Ikram MA, van der Lijn F, et al. The thyroid hormone receptor α locus and white matter lesions: a role for the clock gene REV-ERBα. Thyroid. 2012;22:1181-1186.
134. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011;6: e22552.
135. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623-1629.
136. van der Deure WM, Appelhof BC, Peeters RP, et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf). 2008; 69:804-811.
137. Guo TW, Zhang FC, Yang MS, et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. J Med Genet. 2004;41:585-590.
138. Zhang K, Xi H, Wang X, et al. A family-based association study of DIO2 and children mental retardation in the Qinba region of China. J Hum Genet. 2012;57:14-17.
139. Guo TW, Zhang FC, Gao JJ, et al. Polymorphisms in the TSHR (thyrotropin receptor) gene on chromosome 14q31 are not associated with mental retardation in the iodinedeficient areas of China. Neurosci Lett. 2005;382:179-184.
140. Waung JA, Bassett JH, Williams GR. Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab. 2012;23:155-162.
141. Lee JS, Buzková P, Fink HA, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med. 2010;170:1876-1883.
142. Heemstra KA, Hoftijzer H, van der Deure WM, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res. 2010;25:1385-1391.
143. Bassett JH, Boyde A, Howell PG, et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci USA. 2010;107:7604-7609.
144. Baliram R, Sun L, Cao J, et al. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest. 2012;122:3737-3741.
145. Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;503:129-136.
146. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115:151-162.
147. Galliford TM, Murphy E, Williams AJ, Bassett JH, Williams GR. Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone? Minerva Endocrinol. 2005;30:237-246.
148. Liu RD, Chen RX, Li WR, et al. The Glu727 allele of thyroid stimulating hormone receptor gene is associated with osteoporosis. N Am J Med Sci. 2012;4:300-304.
149. Bochukova E, Schoenmakers N, Agostini M, et al. A mutation in the thyroid hormone receptor α gene. N Engl J Med. 2012;366:243-249.
150. van Mullem A, van Heerebeek R, Chrysis D, et al. Clinical phenotype and mutant TRα1. N Engl J Med. 2012;366: 1451-1453.
151. van Mullem AA, Visser TJ, Peeters RP. Clinical consequences of mutations in thyroid hormone receptor-α1. Eur Thyroid J. 2014;3:17-24.
152. Moran C, Agostini M, Visser WE, et al. Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)α1 and TRα2: clinical, biochemical, and genetic analyses of three related patients. Lancet Diabetes Endocrinol. 2014;2:619-626.
153. Moran C, Schoenmakers N, Agostini M, et al. An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α. J Clin Endocrinol Metab. 2013;98:4254-4261.
154. Medici M, Rivadeneira F, van der Deure WM, et al. A large-scale population-based analysis of common genetic variation in the thyroid hormone receptor α locus and bone. Thyroid. 2012;22:223-224.
155. Meulenbelt I, Min JL, Bos S, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet. 2008;17:1867-1875.
156. Bos SD, Bovée JV, Duijnisveld BJ, et al. Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues. Ann Rheum Dis. 2012;71:1254-1258.
157. Meulenbelt I, Bos SD, Chapman K, et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Ann Rheum Dis. 2011;70:164-167.
158. Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the β-3-adrenergic receptor. Diabetes. 2002;51:880-883.
159. Fiorito M, Torrente I, De Cosmo S, et al. Interaction of DIO2 T92A and PPARγ2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring). 2007;15:2889-2895.
160. Grarup N, Andersen MK, Andreasen CH, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab. 2007;92:363-366.
161. Maia AL, Dupuis J, Manning A, et al. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid. 2007; 17:199-202.
162. Nair S, Muller YL, Ortega E, Kobes S, Bogardus C, Baier LJ. Association analyses of variants in the DIO2 gene with early-onset type 2 diabetes mellitus in Pima Indians. Thyroid. 2012;22:80-87.
163. Peeters RP, van der Deure WM, van den Beld AW, et al. The Asp727Glu polymorphism in the TSH receptor is as-sociated with insulin resistance in healthy elderly men. Clin Endocrinol (Oxf). 2007;66:808-815.
164. Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur J Endocrinol. 2010;163:427-434.
165. Estivalet AA, Leiria LB, Dora JM, et al. D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity (Silver Spring). 2011;19:825-832.
166. Canani LH, Leie MA, Machado WE, Capp C, Maia AL. Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. Hypertension. 2007;49:e47.
167. Maia AL, Hwang SJ, Levy D, Larson MG, Larsen PR, Fox CS. Lack of association between the type 2 deiodinase A/G polymorphism and hypertensive traits: the Framingham Heart Study. Hypertension. 2008;51:e22-e23.
168. van der Deure WM, Peeters RP, Uitterlinden AG, et al. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study. Clin Endocrinol (Oxf). 2009; 71:137-144.
169. García SI, Porto PI, Dieuzeide G, et al. Thyrotropin-releasing hormone receptor (TRHR) gene is associated with essential hypertension. Hypertension. 2001;38:683-687.
170. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology. 2006;147:4036-4043.
171. SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-799.
172. Davies TF, Yin X, Latif R. The genetics of the thyroid stimulating hormone receptor: history and relevance. Thyroid. 2010;20:727-736.
173. Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun. 2007;28:85-98.
174. Wiersinga WM. Thyroid autoimmunity. Endocr Dev. 2014;26:139-157.
175. Weetman AP. The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto. Eur Thyroid J. 2013;1:243-250.
176. Cooper JD, Simmonds MJ, Walker NM, et al. Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet. 2012;21:5202-5208.
177. Denny JC, Crawford DC, Ritchie MD, et al. Variants near FOXE1are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome-and phenome-wide studies.Am J Hum Genet. 2011; 89:529-542.
178. Eriksson N, Tung JY, Kiefer AK, et al. Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One. 2012;7:e34442.
179. Simmonds MJ, Howson JM, Heward JM, et al. Anovel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet. 2007;16:2149-2153.
180. Gough SC, Simmonds MJ. The HLA region and autoimmunedisease: associations and mechanisms of action. Curr Genomics. 2007;8:453-465.
181. Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005;76:561-571.
182. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121:3635-3644.
183. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703-707.
184. Orrú V, Tsai SJ, Rueda B, et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet. 2009;18:569-579.
185. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008;40:1216-1223.
186. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab. 2004;89:5862-5865.
187. Li Y, He X, Schembri-King J, Jakes S, Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol. 2000;164: 5199-5206.
188. Dubois PC, Trynka G, Franke L, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 2010;42:295-302.
189. Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012;44:676-680.
190. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genomewide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42:508-514.
191. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646-6656.
192. Fujikawa K, Miletic AV, Alt FW, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med. 2003;198:1595-1608.
193. Fraser HI, Dendrou CA, Healy B, et al. Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene. J Immunol. 2010;184:5075-5084.
194. Bamforth JS, Hughes IA, Lazarus JH, Weaver CM, Harper PS. Congenital hypothyroidism, spiky hair, and cleft palate. J Med Genet. 1989;26:49-51.
195. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009; 41:460-464.
196. Köhler A, Chen B, Gemignani F, et al. Genome-wide association study on differentiated thyroid cancer. J Clin Endocrinol Metab. 2013;98:E1674-E1681.
197. Takahashi M, Saenko VA, Rogounovitch TI, et al. The FOXE1 locus is a major genetic determinant for radiationrelated thyroid carcinoma in Chernobyl. Hum Mol Genet. 2010;19:2516-2523.
198. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf). 2009;71:434-439.
199. Chu X, Pan CM, Zhao SX, et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet. 2011;43:897-901.
200. Zhao SX, Xue LQ, Liu W, et al. Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum Mol Genet. 2013;22:3347-3362.
201. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35:59-105.
202. Ericsson UB, Christensen SB, Thorell JI. Ahigh prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay. Clin Immunol Immunopathol. 1985;37:154-162.
203. Jacobson EM, Concepcion E, Ho K, Kopp P, Vono Toniolo J, Tomer Y. cDNA immunization of mice with human thyroglobulin generates both humoral and T cell responses: a novel model of thyroid autoimmunity. PLoS One. 2011;6:e19200.
204. Nielsen CH, Hegedüs L, Leslie RG. Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur J Immunol. 2004;34:263-272.
205. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400-404.
206. Castagné R, Zeller T, Rotival M, et al. Influence of sex and genetic variability on expression of X-linked genes in human monocytes. Genomics. 2011;98:320-326.
207. Kirchner J, Bevan MJ. ITM2 Ais induced during thymocyte selection and T cell activation and causes downregulation of CD8 when overexpressed in CD4(+)CD8(+) double positive thymocytes. J Exp Med. 1999;190:217-228.
208. Chu X, Shen M, Xie F, et al. An X chromosome-wide association analysis identifies variants in GPR174 as a risk factor for Graves' disease. J Med Genet. 2013;50:479-485.
209. Cooper JD, Smyth DJ, Smiles AM, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet. 2008;40:1399-1401.
210. Sironi M, Guerini FR, Agliardi C, et al. An evolutionary analysis of RAC2 identifies haplotypes associated with human autoimmune diseases. Mol Biol Evol. 2011;28:3319-3329.
211. Benvenuti F, Hugues S, Walmsley M, et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science. 2004;305:1150-1153.
212. Boyer L, Magoc L, Dejardin S, et al. Pathogen-derived effectors trigger protective immunity via activation of the Rac2 enzyme and the IMD or Rip kinase signaling pathway. Immunity. 2011;35:536-549.
213. Li B, Yu H, Zheng W, et al. Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. Science. 2000;288:2219-2222.
214. Walmsley MJ, Ooi SK, Reynolds LF, et al. Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science. 2003;302:459-462.
215. Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci USA. 2000;97: 4654-4659.
216. Kumar KR, Li L, Yan M, et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science. 2006; 312:1665-1669.
217. Wandstrat AE, Nguyen C, Limaye N, et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity. 2004;21:769-780.
218. Menard L, Cantaert T, Chamberlain N, et al. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. J Allergy Clin Immunol. 2014;133:1149-1161.
219. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286:525-528.
220. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514-523.
221. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
222. Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet. 2010;42:614-618.
223. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:383-392.
224. Williams FM, Carter AM, Hysi PG, et al. Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol. 2013;73:16-31.
225. Tang W, Teichert M, Chasman DI, et al. A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet Epidemiol. 2013;37:512-521.
226. He M, Wu C, Xu J, et al. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. Gut. 2014;63:143-151.
227. Dichgans M, Malik R, König IR, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis ofcommonvariants. Stroke. 2014; 45:24-36.
228. Yamamoto F, Cid E, Yamamoto M, Blancher A. ABO research in the modern era of genomics. Transfus Med Rev. 2012;26:103-118.
229. Medici M, Porcu E, Pistis G, et al. Identification of novel genetic loci associated with thyroid peroxidase antibodies and clinical thyroid disease. PLoS Genet. 2014;10: e1004123.
230. Kwak SH, Park YJ, Go MJ, et al. A genome-wide association study on thyroid function and anti-thyroid peroxidase antibodies in Koreans. Hum Mol Genet. 2014;23: 4433-4442.
231. Muto A, Hoshino H, Madisen L, et al. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. Embo J. 1998;17:5734-5743.
232. Plagnol V, Howson JM, Smyth DJ, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 2011;7:e1002216.
233. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42: 1118-1125.
234. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-219.
235. Wu Y, Dowbenko D, Spencer S, et al. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem. 2000;275:21477-21485.
236. Bossowski A, Czarnocka B, Bardadin K, et al. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Autoimmunity. 2008;41:163-173.
237. Wang SH, Baker JR. The role of apoptosis in thyroid autoimmunity. Thyroid. 2007;17:975-979.
238. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 2012;124: 325-338.
239. Magaña JJ, Velázquez-Pérez L, Cisneros B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol. 2013; 47:90-104.
240. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480:201-208.
241. Rawal R, Teumer A, Völzke H, et al. Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function. Hum Mol Genet. 2012; 21:3275-3282.
242. Zhan M, Chen G, Pan CM, et al. Genome-wide association study identifies a novel susceptibility gene for serum TSH levels in Chinese populations. Hum Mol Genet. 2014;23: 5505-5517.
243. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
244. Jorde R, Schirmer H, Wilsgaard T, et al. The phosphodiesterase 8B gene rs4704397 is associated with thyroid function, risk of myocardial infarction, and body height: the Tromsø study. Thyroid. 2014;24:215-222.
245. Roef GL, Rietzschel ER, De Meyer T, et al. Associations of rs4704397 in phosphodiesterase 8B with thyrotropin and thyroid hormone concentrations. Thyroid. 2013;23:376-377.
246. Taylor PN, Panicker V, Sayers A, et al. A meta-analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. Eur J Endocrinol. 2011;164:773-780.
247. Granfors M, Karypidis H, Hosseini F, et al. Phosphodiesterase 8B gene polymorphism in women with recurrent miscarriage: a retrospective case control study. BMC Med Genet. 2012;13:121.
248. Shields BM, Freathy RM, Knight BA, et al. Phosphodiesterase 8B gene polymorphism is associated with subclinical hypothyroidism in pregnancy. J Clin Endocrinol Metab. 2009;94:4608-4612.
249. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes bothcAMPandcGMP(PDE10A). J BiolChem. 1999;274:18438-18445.
250. Volpato CB, De Grandi A, Gögele M, et al. Linkage and association analysis of hyperthyrotropinaemia in an Alpine population reveal two novel loci on chromosomes 3q28-29 and 6q26-27. J Med Genet. 2011;48:549-556.
251. Teumer A, Rawal R, Homuth G, et al. Genome-wide association study identifies four genetic loci associated with thyroid volume and goiter risk. Am J Hum Genet. 2011; 88:664-673.
252. Grasberger H, Van Sande J, Hag-Dahood Mahameed A, Tenenbaum-Rakover Y, Refetoff S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab. 2007;92:2816-2820.
253. Zhou R, Bonneaud N, Yuan CX, et al. SOX9 interacts with a component of the human thyroid hormone receptor-associated protein complex. Nucleic Acids Res. 2002;30: 3245-3252.
254. das Neves L, Duchala CS, Tolentino-Silva F, et al. Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum. Proc Natl Acad Sci USA. 1999;96:11946-11951.
255. Fernández LP, López-Márquez A, Martínez AM, Gómez-López G, Santisteban P. New insights into FoxE1 functions: identification of direct FoxE1 targets in thyroid cells. PLoS One. 2013;8:e62849.
256. Nakazato M, Chung HK, Ulianich L, Grassadonia A, Suzuki K, Kohn LD. Thyroglobulin repression of thyroid transcription factor 1 (TTF-1) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression. Mol Cell Biol. 2000;20:8499-8512.
257. Ortiz L, Aza-Blanc P, Zannini M, Cato AC, Santisteban P. The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription. J Biol Chem. 1999;274: 15213-15221.
258. Klein M, Catargi B. VEGF in physiological process and thyroid disease. Ann Endocrinol (Paris). 2007;68:438-448.
259. Gérard AC, Poncin S, Audinot JN, Denef JF, Colin IM. Iodide deficiency-induced angiogenic stimulus in the thyroid occurs via HIF-and ROS-dependent VEGF-A secretion from thyrocytes. Am J Physiol Endocrinol Metab. 2009;296:E1414-E1422.
260. Hick AC, Delmarcelle AS, Bouquet M, et al. Reciprocal epithelial:endothelial paracrine interactions during thyroid development govern follicular organization and Ccells differentiation. Dev Biol. 2013;381:227-240.
261. Guo M, Liu W, Serra S, Asa SL, Ezzat S. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res. 2012;72:2017-2027.
262. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev Biol. 2001;231:47-62.
263. Feldt-Rasmussen U. Interactions between growth hormone and the thyroid gland-with special reference to biochemical diagnosis. Curr Med Chem. 2007;14:2783-2788.
264. Laron Z. Interactions between the thyroid hormones and the hormones of the growth hormone axis. Pediatr Endocrinol Rev. 2003;1(suppl 2):244-249; discussion 250.
265. Thomas GA, Davies HG, Williams ED. Site of production of IGF1 in the normal and stimulated mouse thyroid. J Pathol. 1994;173:355-360.
266. Eggo MC, King WJ, Black EG, Sheppard MC. Functional human thyroid cells and their insulin-like growth factorbinding proteins: regulation by thyrotropin, cyclic 3',5' adenosine monophosphate, and growth factors. J Clin Endocrinol Metab. 1996;81:3056-3062.
267. Wescombe L, Lahooti H, Gopinath B, Wall JR. The cardiac calsequestrin gene (CASQ2) is up-regulated in the thyroid in patients with Graves' ophthalmopathy-support for a role of autoimmunity against calsequestrin as the triggering event. Clin Endocrinol (Oxf). 2010;73:522-528.
268. Lantz KA, Vatamaniuk MZ, Brestelli JE, Friedman JR, Matschinsky FM, Kaestner KH. Foxa2 regulates multiple pathways of insulin secretion. J Clin Invest. 2004;114: 512-520.
269. Dubois F, Vandermoere F, Gernez A, et al. Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. Mol Cell Proteomics. 2009;8:2487-2499.
270. Wolfrum C, Besser D, Luca E, Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3β/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci USA. 2003;100: 11624-11629.
271. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs. 2013;13:151-162.
272. Lindquist KJ, Jorgenson E, Hoffmann TJ, Witte JS. The impact of improved microarray coverage and larger sample sizes on future genome-wide association studies. Genet Epidemiol. 2013;37:383-392.
273. Zenewicz LA, Abraham C, Flavell RA, Cho JH. Unraveling the genetics of autoimmunity. Cell. 2010;140:791-797.
274. Huber AK, Concepcion ES, Gandhi A, et al. Analysis of immune regulatory genes' copy number variants in Graves' disease. Thyroid. 2011;21:69-74.
275. Aschard H, Lutz S, Maus B, et al. Challenges and opportunities in genome-wide environmental interaction (GWEI) studies. Hum Genet. 2012;131:1591-1613.
276. Fricchione GL, Stefano GB. The stress response and autoimmunoregulation. Adv Neuroimmunol. 1994;4:13-27.
277. Hargreaves CE, Grasso M, Hampe CS, et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol. 2013;190:5373-5381.
278. Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98:E364-E369.
279. Yan J, Takahashi T, Ohura T, et al. Combined linkage analysis and exome sequencing identifies novel genes for familial goiter. J Hum Genet. 2013;58:366-377.
280. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690.
281. Sun Y, Bak B, Schoenmakers N, et al. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet. 2012;44:1375-1381.
282. Zevenbergen C, Klootwijk W, Peeters RP, et al. Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase. J Clin Endocrinol Metab. 2014;99:E2429-E2436.
283. Kilpinen H, Barrett JC. Hownext-generation sequencing is transforming complex disease genetics. Trends Genet. 2013;29:23-30.
284. Ku CS, Tan EK, Cooper DN. From the periphery to centre stage: de novo single nucleotide variants play a key role in human genetic disease. J Med Genet. 2013;50:203-211.
285. Exome Variant Server. NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. http://evs.gs.washington.edu/EVS/.
286. Ambrosio R, Damiano V, Sibilio A, et al. Epigenetic control of type 2 and 3 deiodinases in myogenesis: role of lysine-specific demethylase enzyme and FoxO3. Nucleic Acids Res. 2013;41:3551-3562.
287. Taylor PN, Porcu E, Chew S, et al. Whole-genome sequence-based analysis of thyroid function. Nat Commun. March 6, 2015. doi: 10.1038/ncomms6681.